Chairman
Lee-Cheng Liu

With the increased integration of digital health, smart healthcare and AI into almost every aspect of the healthcare sector, innovation is blossoming and the industry is advancing at an increasingly rapid pace. The drug discovery, medical device and pharmaceutical sectors are stronger and more efficient than before; developmental and regulatory timelines have shortened, and the industry is more globally-connected than ever. But with the new threat of tariffs and other barriers to free trade upending long established cross border supply chains, uncertainty is the new normal.
 
While India, China and Ireland as major manufacturing hubs and suppliers of ATP will be bearing the brunt of such uncertainty, Taiwan's biomedical industry is relatively sheltered from the worst of these effects. While no one truly knows what the future holds, Taiwan's biomedical industries are currently in a strong place; revenues for the combined biotechnology, pharmaceutical, medical devices and health and well-being sectors reached NT$757.8 billion (US$20 billion) in 2023, an increase of more than 8 percent over 2022. Investment into this industry reached NT$55 billion (US$2.4 billion). As of the end of 2023, 134 biomedical companies were listed on Taiwan's stock exchanges, with a total market capitalization of NT$1.31 trillion (US$41 billion) 
 
We're better placed than ever to take advantage of new opportunities, to enter new markets, and to explore new collaborations. Proven under fire during the pandemic, Taiwan continues to stand out as an attractive alternative to China for the rapid rollout of high quality healthcare products; pharmaceuticals, vaccines, and medical devices, including personal protective equipment (PPE). If and when the next global healthcare crisis hits, Taiwan is ready, and so is Taiwan BIO!
 
Taiwan BIO works tirelessly on behalf of its members to facilitate networking and business opportunities. With the biomedical industry so reliant on international collaboration and partnership, it is my hope that Taiwan BIO continues to grow and expand its international reach. A reflection of Taiwan's strong international standing, Secretary General of Taiwan BIO, Dr. Wallace Lin, was last year elected to his current position of Vice Chair of the International Council of Biotechnology Associations (ICBA), a great honor. 
 
We welcome individuals, companies and institutes to join Taiwan BIO. Membership brings a host of benefits, including reduced registration fees to important events such as BIO Asia–Taiwan; participation in international forums and networking meetings, both online and here in Taiwan; and a host of other benefits. Most importantly, joining Taiwan BIO provides you with a seat at the table; a chance to join our many policy and industry committees, providing invaluable engagement with our 300+ corporate members, a community ready and willing to work with the global community to together bring products and services to world markets.
 
Hope to see you all at BIO Asia–Taiwan 2025!